Condition
HIV/HCV Coinfection
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Unknown1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00866021Phase 4CompletedPrimary
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
NCT01350648Completed
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
NCT02102451Unknown
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
NCT01707472Phase 2Completed
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
NCT02762383Phase 3TerminatedPrimary
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
Showing all 5 trials